Trial reportCancer immunology research2016
TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination.
Trial report in Cancer immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Impact of molecular and clinical variables on survival outcome with immunotherapy for glioblastoma patients: A systematic review and meta-analysis.CNS neuroscience & therapeutics · 2022Pooled it
- Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme.Human vaccines & immunotherapeutics · 2017Pooled it
- Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial.British journal of cancer · 2024Trial
- Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.Acta neuropathologica communications · 2018Trial
- Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer.Medicine · 2018Trial
- Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.PLoS medicine · 2017Trial
- Tumor antigen only (TAO) vaccine platforms for glioblastoma therapeutics: a systematic review of evidence from clinical trials.EClinicalMedicine · 2026Review
- The promise of immunotherapy for central nervous system tumours.Nature reviews. Immunology · 2026Review
- Biomarkers for predicting and monitoring the efficacy of cancer vaccines.Frontiers in oncology · 2026Review
- Tumor-infiltrating lymphocytes-derived CD8Oncoimmunology · 2025Article
- Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy.Immuno-oncology technology · 2025Review
- Gemistocytic tumor cells programmed for glial scarring characterize T cell confinement in IDH-mutant astrocytoma.Nature communications · 2025Article
- Peripheral blood TCR repertoire improves early detection across multiple cancer types utilizing a cancer predictor.Frontiers in oncology · 2025Article
- Human TCR repertoire in cancer.Cancer medicine · 2024Review
- Quantifiable TCR repertoire changes in prediagnostic blood specimens among patients with high-grade ovarian cancer.Cell reports. Medicine · 2024Article
- Comprehensive application of AI algorithms with TCR NGS data for glioma diagnosis.Scientific reports · 2024Article
- Self-supervised learning of T cell receptor sequences exposes core properties for T cell membership.Science advances · 2024Article
- The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.Frontiers in immunology · 2024Review
- Genomic, transcriptomic, and T cell receptor profiling in stratifying response to first-line chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma.Frontiers in oncology · 2024Article
- A novel statistical method for decontaminating T-cell receptor sequencing data.Briefings in bioinformatics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
Although immunotherapeutic strategies are emerging as adjunctive treatments for cancer, sensitive methods of monitoring the immune response after treatment remain to be established. We used a novel next-generation sequencing approach to determine whether quantitative assessments of tumor-infiltrating lymphocyte (TIL) content and the degree of overlap of T-cell receptor (TCR) sequences in brain tumors and peripheral blood were predictors of immune response and overall survival in glioblastoma patients treated with autologous tumor lysate-pulsed dendritic cell immunotherapy. A statistically significant correlation was found between a higher estimated TIL content and increased time to progression and overall survival. In addition, we were able to assess the proportion of shared TCR sequences between tumor and peripheral blood at time points before and after therapy, and found the level of TCR overlap to correlate with survival outcomes. Higher degrees of overlap, or the development of an increased overlap following immunotherapy, was correlated with improved clinical outcome, and may provide insights into the successful, antigen-specific immune response. Cancer Immunol Res; 4(5); 412-8. ©2016 AACR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.